Treosulfan is an alkylating agent that has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU) for the treatment of ovarian cancer. Treosulfan is a bifunctional alkylating agent with antineoplastic activity derived from its nonenzymatic conversion to epoxide compounds that react with nucleophilic centers of DNA. It is used for the treatment of ovarian carcinoma. The compound differs structurally from busulfan only by the presence of two hydroxyl groups. However, these changes impart a different metabolic profile and mechanism of action; in contrast to busulfan, treosulfan is metabolized in vivo to active epoxides, dL-diepoxybutane, which serve as bifunctional alkylating agents.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Treosulfan, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.